These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 6134650)

  • 1. Minimal increases in glucagon levels enhance glucose production in man with partial hypoinsulinemia.
    Lins PE; Wajngot A; Adamson U; Vranic M; Efendić S
    Diabetes; 1983 Jul; 32(7):633-6. PubMed ID: 6134650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperglycemia and beta-cell adaptation during prolonged somatostatin infusion with glucagon replacement in man.
    Ward WK; Halter JB; Best JD; Beard JC; Porte D
    Diabetes; 1983 Oct; 32(10):943-7. PubMed ID: 6137430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The influence of graded hyperglycemia with and without physiological hyperinsulinemia on forearm glucose uptake and other metabolic responses in man.
    Jackson RA; Hamling JB; Blix PM; Sim BM; Hawa MI; Jaspan JB; Belin J; Nabarro JD
    J Clin Endocrinol Metab; 1986 Sep; 63(3):594-604. PubMed ID: 2874153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pancreatic somatostatin is a mediator of glucagon inhibition by hyperglycemia.
    Klaff LJ; Taborsky GJ
    Diabetes; 1987 May; 36(5):592-6. PubMed ID: 2883057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics.
    Baron AD; Schaeffer L; Shragg P; Kolterman OG
    Diabetes; 1987 Mar; 36(3):274-83. PubMed ID: 2879757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Somatostatin-induced changes in insulin and glucagon secretion in normal and diabetic dogs.
    Sakurai H; Dobbs R; Unger RH
    J Clin Invest; 1974 Dec; 54(6):1395-402. PubMed ID: 4436439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of glucagon replacement on the hyperglycemic and hyperketonemic response to prolonged somatostatin infusion in normal man.
    Sherwin RS; Tamborlane W; Hendler R; Saccá L; DeFronzo RA; Felig P
    J Clin Endocrinol Metab; 1977 Nov; 45(5):1104-7. PubMed ID: 925134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interaction of somatostatin, glucagon, and insulin on hepatic glucose output in the normal dog.
    Altszuler N; Gottlieb B; Hampshire J
    Diabetes; 1976 Feb; 25(2):116-21. PubMed ID: 1248672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucose homeostasis during prolonged suppression of glucagon and insulin secretion by somatostatin.
    Sherwin RS; Hendler R; DeFronzo R; Wahren J; Felic P
    Proc Natl Acad Sci U S A; 1977 Jan; 74(1):348-52. PubMed ID: 264686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Restoration of stable metabolic conditions during islet suppression in dogs.
    Bradley DC; Bergman RN
    Am J Physiol; 1992 Apr; 262(4 Pt 1):E532-8. PubMed ID: 1348903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Altered ability of the liver to produce glucose following a period of glucagon deficiency.
    Deri JJ; Williams PE; Steiner KE; Cherrington AD
    Diabetes; 1981 Jun; 30(6):490-5. PubMed ID: 6112181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hyperglycemia per se (insulin and glucagon withdrawn) can inhibit hepatic glucose production in man.
    Liljenquist JE; Mueller GL; Cherrington AD; Perry JM; Rabinowitz D
    J Clin Endocrinol Metab; 1979 Jan; 48(1):171-5. PubMed ID: 422700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prolonged infusion of somatostatin with glucagon replacement increases plasma glucose and glucose turnover in man.
    Ward WK; Best JD; Halter JB; Porte D
    J Clin Endocrinol Metab; 1984 Mar; 58(3):449-53. PubMed ID: 6141177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of morphine on glucose homeostasis in the conscious dog.
    Radosevich PM; Williams PE; Lacy DB; McRae JR; Steiner KE; Cherrington AD; Lacy WW; Abumrad NN
    J Clin Invest; 1984 Oct; 74(4):1473-80. PubMed ID: 6148357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of arginine on splanchnic glucose metabolism in man.
    Bratusch-Marrain P; Björkman O; Hagenfeldt L; Waldhäusl W; Wahren J
    Diabetes; 1979 Feb; 28(2):126-31. PubMed ID: 421970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of glucagon on glucose production during insulin deficiency in the dog.
    Cherrington AD; Lacy WW; Chiasson JL
    J Clin Invest; 1978 Sep; 62(3):664-77. PubMed ID: 690190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucose disposal during insulinopenia in somatostatin-treated dogs. The roles of glucose and glucagon.
    Shulman GI; Liljenquist JE; Williams PE; Lacy WW; Cherrington AD
    J Clin Invest; 1978 Aug; 62(2):487-91. PubMed ID: 670404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin, glucagon, and somatostatin in normal physiology and diabetes mellitus.
    Felig P; Wahren J; Sherwin R; Hendler R
    Diabetes; 1976 Dec; 25(12):1091-9. PubMed ID: 992227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transient hepatic response to glucagon in man: role of insulin and hyperglycemia.
    Ferrannini E; DeFronzo RA; Sherwin RS
    Am J Physiol; 1982 Feb; 242(2):E73-81. PubMed ID: 7039338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extrapancreatic effect of somatostatin infusion to increase glucose clearance.
    Bergman RN; Ader M; Finegood DT; Pacini G
    Am J Physiol; 1984 Sep; 247(3 Pt 1):E370-9. PubMed ID: 6148014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.